SIR 2446M
Alternative Names: SIR-2446; SIR-2446MLatest Information Update: 17 Mar 2022
Price :
$50 *
At a glance
- Originator Sironax Aus Pty
- Class Antidementias
- Mechanism of Action RIPK1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alzheimer's disease; Multiple sclerosis
Most Recent Events
- 17 Mar 2022 CTPs 345327: updated intro, KDM and dev T for trial initiation
- 17 Dec 2021 Phase-I clinical trials in Alzheimer's disease (In volunteers) in Australia (PO) (ACTRN12621001621808)
- 17 Dec 2021 Phase-I clinical trials in Multiple sclerosis (In volunteers) in Australia (PO) (ACTRN12621001621808)